US FDA Reviewing Data To Determine Need For Biosimilar Suffixes

 
• By Derrick Gingery
  
FDA staff will review biosimilar adverse event databases to determine whether the nonproprietary name suffix still is necessary. (Shutterstock)
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Biosimilars

More from United States